Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today an additional $200M financing at a value of $3.1 billion dollars. The investors include Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, Revolution Growth, and funds and accounts managed by T. Rowe Price. With this latest round, the company has raised $520 million since its founding in September 2015.Founded in 2015, Tempus has the largest
Read More
Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant
LunaPBC Raises $4.6M to Fuel Community-Owned Genomic & Health Data Platform
LunaPBC, founder of LunaDNA, the first community-owned genomic and health data platform, has raised $4.6 million from ARCH Venture Partners, Bain Capital Ventures, F-Prime Capital, Illumina Ventures, and Osage University Partners. The latest round brings the company’s total funding to date to $7.6 million.
First Community-Owned Health & DNA Research Platform
Founded in 2017 on the belief that health data sharing and community ownership are the new philanthropy, LunaDNA is the first
Read More
7 Trends Accelerating “TechBio” – The Life Sciences and Computer Sciences Convergence
We are now living in what I’m calling the
TechBio revolution. That’s not a typo that should read BioTech, but rather a
new way of looking at the convergence of technology and biology.
TechBio is defined as an engineering-first approach of biological processes for industrial, and other purposes, especially the genetic manipulation of microorganisms for the production of antibiotics, hormones, and so on. A process that uses AI and data-enabled discovery to complement the exploration of
Read More
Digital Twin Technology: Should Healthcare Jump on the Bandwagon?
While healthcare is known for not jumping to conclusions very fast when investing in new technology, the industry starts to pick up the pace. Such “newcomers” as blockchain, IoT, VR, and AR get a well-deserved appraisal and become an integral part of next-gen custom healthcare software aimed at supporting personalized treatment and predictable patient outcomes across a wide range of conditions.
We anticipate that the digital twin technology has good chances to become the next addition to the
Read More
Why 2018 May Have Been A High-Water Mark for Digital Health Funding
Notwithstanding the quite significant stock market turmoil for publicly traded healthcare companies in recent months, the level of private investment activity continued to be quite strong this past quarter. According to Rock Health, 1Q19 registered just under $1.0 billion of investments made in 61 healthcare technology companies, which while below the trailing two year quarterly average of $1.4 billion, still suggests an annual investment pace running toward $4.0 billion. StartUp Health, which
Read More
Medidata Launches New Life Sciences Company, Acorn AI
Life sciences digital transformation company Medidata, today announced the launch of Acorn AI, a new company designed to provide actionable insights across the entire drug continuum – from R&D to commercialization. In addition, the company has appointed Rama Kondru, Ph.D., as the chief information officer for Medidata and Acorn AI’s first CIO to lead the company’s enterprise data strategy, architecture and future platform development – all helping the company to accelerate the creation of
Read More
AdoRx Therapeutics, J&J Team Up to Develop Novel Lung Cancer Therapeutics
AdoRx Therapeutics, a UK based drug discovery company, and Johnson & Johnson are teaming up to develop novel therapeutics for the treatment of lung cancer. As part of the strategic collaboration, AdoRx has granted an exclusive option to research, develop and commercialize novel antagonists within the AdoRx portfolio, and the groups will collaborate on drug discovery and preclinical development activities. AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer-based on
Read More
ICON Acquires Precision Medicine for Oncology Company MolecularMD
ICON, a global provider of drug development solutions and services has acquired MolecularMD, a molecular diagnostic specialty laboratory that enables the development and commercialization of precision medicines in oncology. The acquisition of MolecularMD’s extensive scientific and clinical biomarker experience expands the ICON’s capabilities in molecular diagnostic testing and also adds expanded testing platforms, including next-generation sequencing and immunohistochemistry, to ICON’s
Read More
Accenture Launches Life Science Open Partner Ecosystem to Advance Drug Discovery
Accenture, today announced it has created an open partner ecosystem developed in partnership with Merck and Amazon Web Services (AWS) designed to help independent software vendors (ISVs) and life sciences companies team more effectively to accelerate drug discovery efforts and, ultimately, improve patient outcomes.Life Sciences Partner Ecosystem Overview Built on Amazon Web Services and supported by ongoing work between Accenture and AWS through the Accenture AWS Business Group, the platform is
Read More
H1 Launches ‘Strategy as a Service’ Offering for Life Science Companies
H1, a company helping healthcare organizations with live data insights to help fight diseases, today launched a new Strategy as a Service offering designed to help clients accelerate the market research phase of drug development.The company’s new DaVinci service begins at $10,000, which can help clients cut time-to-market in half, spans:- Market Landscape: Validate your strategy against an up-to-date, comprehensive picture of products and patient needs in your market.- Competitive
Read More
